<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007808</url>
  </required_header>
  <id_info>
    <org_study_id>2020-G001-P2</org_study_id>
    <nct_id>NCT05007808</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee</brief_title>
  <official_title>Phase 2 Multicenter, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Efficacy, Safety, and Local Tolerability of G001 in Patients With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BUZZZ Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veristat, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BUZZZ Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to&#xD;
      evaluate the efficacy, safety, and local tolerability of G001 topical gel compared to&#xD;
      matching Vehicle topical gel in patients with symptomatic OA of the knee.&#xD;
&#xD;
      Each patient's participation is approximately 7 weeks (~1 week screening, 4 weeks of&#xD;
      treatment, and 2 weeks of post-treatment follow-up). Eligible patients with adequate OA pain&#xD;
      in the index knee are randomized (1:1 allocation ratio) at the Baseline/Flare Visit 1.&#xD;
&#xD;
      Following screening, prior NSAID and/or acetaminophen use is discontinued to allow for&#xD;
      washout and symptom flare. Patients are instructed to rate their worst daily and nightly pain&#xD;
      in their daily diary, as well as to document all study drug applications and any rescue&#xD;
      medication (acetaminophen) use for breakthrough pain. Acetaminophen may be used as rescue&#xD;
      medication only, except within 12 hours prior to the Baseline Visit and within 12 hours prior&#xD;
      to any post-baseline efficacy assessments (Weeks 2, 4, and 5). Patients are instructed to&#xD;
      return to the clinic 3 to 7 days after the last study drug application for Flare Visit 2, and&#xD;
      within approximately 2 weeks after the last study drug application for end-of-study&#xD;
      evaluations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in WOMAC Pain Subscale Score</measure>
    <time_frame>Week 4</time_frame>
    <description>0-20 scale, with higher scores indicating worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in WOMAC Physical Function Subscale score</measure>
    <time_frame>Week 4</time_frame>
    <description>0-68 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in WOMAC Total score</measure>
    <time_frame>Week 4</time_frame>
    <description>0-96 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in WOMAC Stiffness Subscale score</measure>
    <time_frame>Week 4</time_frame>
    <description>0-8 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in WOMAC Total and Subscale Scores</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Week 4 to Week 5 in WOMAC Total and Subscale Scores</measure>
    <time_frame>Week 4 to Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst daily and nightly pain severity scores (11-point pain NRS) from patient diary</measure>
    <time_frame>Weeks 4 and 5</time_frame>
    <description>0-10 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Assessment (PGA) of disease activity over time</measure>
    <time_frame>Weeks 2, 4 and 5</time_frame>
    <description>0-4 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Investigator Global Assessment (IGA) of disease activity over time</measure>
    <time_frame>Weeks 2, 4 and 5</time_frame>
    <description>0-4 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA of overall treatment benefit</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>0-4 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA of overall treatment benefit</measure>
    <time_frame>Weeks 2 and 4</time_frame>
    <description>0-4 scale, with higher scores indicating worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency and severity of adverse events (AEs), study drug-related AEs, serious AEs, and AEs leading to study drug discontinuation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number and percentage of participants with AEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency and severity of application site AEs</measure>
    <time_frame>5 weeks</time_frame>
    <description>Number and percentage of participants with application site AEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Skin irritation test scores</measure>
    <time_frame>Weeks 2, 4, and 6</time_frame>
    <description>0-10 scale, with higher scores indicating worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in safety laboratory test results</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean changes (descriptive) and shifts from normal baseline to laboratory values outside reference ranges</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs measurements</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean changes (descriptive) from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in physical examination</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number and percentage of participants with clinically significant abnormal findings</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG QT interval</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number and percentage of participants with clinically significant abnormal results</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG QTc interval</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number and percentage of participants with clinically significant abnormal results</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG QRS interval</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number and percentage of participants with clinically significant abnormal results</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG PR interval</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number and percentage of participants with clinically significant abnormal results</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>G001 Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G001 Topical Gel</intervention_name>
    <description>Non-steroidal anti-inflammatory drug for topical administration</description>
    <arm_group_label>G001 Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Gel for topical administration</description>
    <arm_group_label>Vehicle Topical Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of OA of the knee, meeting American College of Rheumatology (ACR)&#xD;
             criteria for classification of idiopathic (primary) OA for at least 6 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Radiologic evidence of OA of the knee of grade 2 (mild) or grade 3 (moderate)&#xD;
             according to Kellgren and Lawrence Radiographic Grading&#xD;
&#xD;
          -  Worst daily pain (within 24 hours prior to Screening and Baseline) in the index knee&#xD;
             between 4 and 8 on the 11-point pain NRS&#xD;
&#xD;
          -  On stable analgesic therapy&#xD;
&#xD;
        At Baseline:&#xD;
&#xD;
        - Development of a flare of pain following washout of stable analgesic (NSAID and/or&#xD;
        acetaminophen) therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiologic evidence of severe OA of the knee (Kellgren and Lawrence grade 4)&#xD;
&#xD;
          -  Secondary OA of the index knee&#xD;
&#xD;
          -  Any other arthritis, included but not limited to rheumatoid arthritis, psoriatic&#xD;
             arthritis, etc.&#xD;
&#xD;
          -  History of pseudo-gout or inflammatory flare-ups&#xD;
&#xD;
          -  History of severe neurological conditions&#xD;
&#xD;
          -  Any other chronic pain conditions (e.g., back pain) or disabling conditions affecting&#xD;
             the joints&#xD;
&#xD;
          -  Patients who are non-ambulatory or require the use of crutches or a walker, or started&#xD;
             using a cane within 30 days prior to Screening&#xD;
&#xD;
          -  Any history of major surgery to the index knee, minor knee surgery, or injury to the&#xD;
             index knee within 1 year prior to Screening&#xD;
&#xD;
          -  Knee arthroscopy (index knee) within 3 months prior to Screening&#xD;
&#xD;
          -  Planned or candidate for knee replacement or knee reconstruction surgery&#xD;
&#xD;
          -  Received intra-articular viscosupplementation/hyaluronate, joint lavage, or other&#xD;
             invasive therapies to the index knee in the past 90 days&#xD;
&#xD;
          -  Treatment with or need for any of the following: (1) oral or intramuscular&#xD;
             corticosteroids within the past 90 days; (2) intra-articular corticosteroid injection&#xD;
             into the index knee within the past 90 days, or into any other joint within the past&#xD;
             30 days; (3) current use of topical corticosteroids on the index knee&#xD;
&#xD;
          -  Prior stable therapy with an opioid analgesic, or anticipated need for opioid&#xD;
             analgesic use during the study&#xD;
&#xD;
          -  Use of sedative hypnotic medication, antidepressants with known analgesic effect,&#xD;
             antipsychotics, antiepileptics, and anti-Parkinson drugs within the past 14 days&#xD;
&#xD;
          -  Regular use of medication for headaches&#xD;
&#xD;
          -  Anticipated use of any oral or topical NSAID (apart from the study drug) during the&#xD;
             study&#xD;
&#xD;
          -  Known sensitivity to the study drug (or any of its ingredients), or NSAIDs, or&#xD;
             presence of contraindications, warnings, or precautions&#xD;
&#xD;
        At Baseline:&#xD;
&#xD;
          -  Worst daily pain (within the past 24 hours) in the contralateral knee assessed as &gt;2&#xD;
             on the 11-point pain NRS scale&#xD;
&#xD;
          -  Non-compliance with the daily diary requirement during the Screening period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre O'Keeffe, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Buzzz Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather M Karabaich</last_name>
    <phone>508-306-6352</phone>
    <email>heather.karabaich@veristat.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aggarwal and Associates Limited</name>
      <address>
        <city>Brampton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manna Research</name>
      <address>
        <city>Lévis</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Recherche GCP Research</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alpha recherche Clinique (1)</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alpha Recherche Clinique (2)</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>G.R.M.O. (Groupe de Recherche en Maladie Osseuses) Inc.</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Recherche Clinique Sigma Inc.</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicor Research Inc.</name>
      <address>
        <city>Sudbury</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward Inc.</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>topical therapy</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

